Celgene Corp. (NASDAQ:CELG) was upgraded by investment analysts at Vetr from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Monday. The brokerage presently has a $129.47 price objective on the biopharmaceutical company’s stock. Vetr‘s target price points to a potential upside of 7.03% from the company’s previous close.

Other equities research analysts have also recently issued research reports about the stock. Canaccord Genuity set a $156.00 price objective on shares of Celgene Corp. and gave the stock a “buy” rating in a research note on Sunday, September 18th. Cowen and Company reissued a “buy” rating and issued a $150.00 price target on shares of Celgene Corp. in a research note on Thursday, July 28th. Leerink Swann reissued a “market perform” rating and issued a $135.00 price target on shares of Celgene Corp. in a research note on Monday, September 12th. Mizuho assumed coverage on shares of Celgene Corp. in a research note on Monday, November 7th. They issued a “buy” rating and a $130.00 price target on the stock. Finally, Jefferies Group reissued a “buy” rating and issued a $137.00 price target on shares of Celgene Corp. in a research note on Tuesday, August 9th. Four investment analysts have rated the stock with a hold rating and twenty-five have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $136.30.

Analyst Recommendations for Celgene Corp. (NASDAQ:CELG)

Shares of Celgene Corp. (NASDAQ:CELG) opened at 120.97 on Monday. The company’s 50-day moving average is $107.40 and its 200-day moving average is $106.27. The stock has a market cap of $93.78 billion, a P/E ratio of 45.94 and a beta of 1.71. Celgene Corp. has a 1-year low of $93.05 and a 1-year high of $127.00.

Celgene Corp. (NASDAQ:CELG) last issued its quarterly earnings data on Thursday, October 27th. The biopharmaceutical company reported $1.58 EPS for the quarter, topping analysts’ consensus estimates of $1.48 by $0.10. The business had revenue of $2.98 billion for the quarter, compared to analysts’ expectations of $2.84 billion. Celgene Corp. had a net margin of 19.71% and a return on equity of 70.48%. The business’s revenue was up 27.8% on a year-over-year basis. During the same quarter last year, the company earned $1.23 EPS. Equities analysts expect that Celgene Corp. will post $5.92 EPS for the current fiscal year.

In other news, Director Richard W. Barker sold 20,000 shares of the company’s stock in a transaction that occurred on Friday, September 23rd. The stock was sold at an average price of $110.82, for a total transaction of $2,216,400.00. Following the completion of the sale, the director now owns 31,332 shares in the company, valued at $3,472,212.24. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Gilla Kaplan sold 9,710 shares of the company’s stock in a transaction that occurred on Thursday, September 15th. The stock was sold at an average price of $106.44, for a total value of $1,033,532.40. Following the sale, the director now owns 72,142 shares of the company’s stock, valued at approximately $7,678,794.48. The disclosure for this sale can be found here. Insiders own 0.97% of the company’s stock.

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. First Financial Corp IN raised its position in shares of Celgene Corp. by 30.9% in the third quarter. First Financial Corp IN now owns 967 shares of the biopharmaceutical company’s stock worth $101,000 after buying an additional 228 shares in the last quarter. Jolley Asset Management LLC raised its position in shares of Celgene Corp. by 58.8% in the second quarter. Jolley Asset Management LLC now owns 1,215 shares of the biopharmaceutical company’s stock worth $120,000 after buying an additional 450 shares in the last quarter. Smithfield Trust Co. raised its position in shares of Celgene Corp. by 12.5% in the second quarter. Smithfield Trust Co. now owns 1,282 shares of the biopharmaceutical company’s stock worth $127,000 after buying an additional 142 shares in the last quarter. Integrated Investment Consultants LLC raised its position in shares of Celgene Corp. by 21.8% in the second quarter. Integrated Investment Consultants LLC now owns 1,339 shares of the biopharmaceutical company’s stock worth $132,000 after buying an additional 240 shares in the last quarter. Finally, Cornerstone Advisors Inc. raised its position in shares of Celgene Corp. by 202.8% in the third quarter. Cornerstone Advisors Inc. now owns 1,320 shares of the biopharmaceutical company’s stock worth $138,000 after buying an additional 884 shares in the last quarter. 77.85% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: “Vetr Inc. Upgrades Celgene Corp. (CELG) to Buy” was first posted by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are reading this article on another site, it was stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this article can be accessed at https://www.thecerbatgem.com/2016/11/23/vetr-inc-upgrades-celgene-corp-celg-to-buy.html.

Celgene Corp. Company Profile

Celgene Corporation (Celgene) is a biopharmaceutical company. The Company together with its subsidiaries is engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

5 Day Chart for NASDAQ:CELG

Receive News & Stock Ratings for Celgene Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corp. and related stocks with our FREE daily email newsletter.